Tradeline, Inc. filters and categorizes new-construction and industry news from regional and professional journals across the country. Here you will find new projects, products, and regulatory updates.
Industry News
Charles River Labs Builds Transgenic Facility
Charles River Laboratories International, a provider of contract services and research animals to the biotech and pharmaceutical industries, has a 68,000-sf transgenic facility under construction at their Wilmington headquarters. Completion of the building is anticipated in spring 2002. Demand for the company’s products increased significantly as the mapping of the human genome revealed genetic similarities between mice and humans.
Rigel Pharmaceuticals Relocates to South San Francisco
Rigel Pharmaceuticals has plans to relocate from 65,000 sf of lab space at the Britannia Pointe Grand Business Park to a new two-building lab facility at Slough Estate’s 22-acre Shearwater development in South San Francisco. The new buildings, which will total 140,000 sf, will begin construction this year. Rigel, whose focus is fluorescent gene marking, anticipates relocating to the new complex in 2002. Completion of the entire seven-building, 570,000-sf Shearwater development is anticipated by summer 2004.
California Dept. of Justice Builds New DNA Lab
The State of California has contracted with Wareham Development for 68,000 sf at the Point Richmond Tech Center to house a new DNA-testing lab for the Department of Justice. Following $300/sf tenant improvements by Wareham, the state will occupy the lab in late 2001, where a DNA database of every criminal in California will be compiled.
Schering-Plough Expands Union Campus
Schering-Plough plans to renovate and expand its mixed-use pilot plant and lab buildings at its campus in Union, consolidating several research groups currently spread throughout the existing 35,000-sf building. Renovations will include a new chiller plant, new entrance and loading dock, new mechanical, electrical, plumbing, fire protection, and control systems throughout the building. Renovation of exterior cladding to permit more natural light in labs and support spaces, and replacement of existing floors with concrete slabs will also be part of the project.
Elan Considers SoCal Consolidation
Elan Corp., based in Dublin, Ireland, may consolidate New Jersey and San Francisco units of its pharmaceuticals division at a new North American headquarters in Sorrento Valley, where its recently-acquired Dura Pharmaceuticals is located. Plans would include expanding research space at the existing facility and possibly constructing an additional structure nearby. Elan focuses on drug development for pain management, cancer, and neurological disorders.
<?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />